| Southern Tennessee Primary Care-winchester Family Medicine | |
|
2118 Cowan Hwy Winchester TN 37398-2637 | |
| (931) 962-4040 | |
| (931) 962-2277 |
| Full Name | Southern Tennessee Primary Care-winchester Family Medicine |
|---|---|
| Speciality | General Practice |
| Location | 2118 Cowan Hwy, Winchester, Tennessee |
| Authorized Official Name and Position | Monic Bowman (PRESIDENT) |
| Authorized Official Contact | 6159207000 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Southern Tennessee Primary Care-winchester Family Medicine 330 Seven Springs Way Brentwood TN 37027-5098 Ph: (615) 920-7000 | Southern Tennessee Primary Care-winchester Family Medicine 2118 Cowan Hwy Winchester TN 37398-2637 Ph: (931) 962-4040 |
| NPI Number | 1164789467 |
|---|---|
| Provider Enumeration Date | 04/12/2012 |
| Last Update Date | 09/24/2022 |
| Medicare PECOS PAC ID | 5991765943 |
|---|---|
| Medicare Enrollment ID | O20041013001206 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164789467 | NPI | - | NPPES |
| 1528095 | Medicaid | TN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208D00000X | General Practice | (* (Not Available)) | Primary |
| Provider Name | Tony M Cox |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1255425450 PECOS PAC ID: 9931005170 Enrollment ID: I20031209000901 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Olan B Kemp |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1538265749 PECOS PAC ID: 5496746786 Enrollment ID: I20040525000462 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Raymond Lee Capps |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1346444742 PECOS PAC ID: 6305819996 Enrollment ID: I20040812001193 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Andrea Kelley Gore Hayes |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295819175 PECOS PAC ID: 1254304991 Enrollment ID: I20040819000533 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Diane Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417940784 PECOS PAC ID: 4789648569 Enrollment ID: I20041112000469 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Charles K Galiwango |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1417900812 PECOS PAC ID: 1658329248 Enrollment ID: I20050111000171 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Guy F Fain |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1184653453 PECOS PAC ID: 6800847278 Enrollment ID: I20050202000710 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Tenzing Chounzom |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1427075894 PECOS PAC ID: 2466403704 Enrollment ID: I20050203000928 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Kim P Zahnke |
|---|---|
| Provider Type | Practitioner - Hospitalist |
| Provider Identifiers | NPI Number: 1033157284 PECOS PAC ID: 5092746255 Enrollment ID: I20050826000675 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Shon P Nolin |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1447275359 PECOS PAC ID: 9436062478 Enrollment ID: I20050826000832 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Linda R Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972608669 PECOS PAC ID: 8628076999 Enrollment ID: I20061121000061 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | James T Mcclure |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1073559803 PECOS PAC ID: 3971571993 Enrollment ID: I20070116000625 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Karen M Gilson |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1104813211 PECOS PAC ID: 4688779093 Enrollment ID: I20070413000159 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Kelly B Golden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1902939655 PECOS PAC ID: 5597858936 Enrollment ID: I20070830000631 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Damian T Szewczyk |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1861403065 PECOS PAC ID: 5698702587 Enrollment ID: I20070831000190 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Troy A Hixson |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1730382458 PECOS PAC ID: 6002902137 Enrollment ID: I20071019000413 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Craig S Swafford |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1053490417 PECOS PAC ID: 7618049339 Enrollment ID: I20080711000312 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mindy D Holloway |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881852671 PECOS PAC ID: 9739240516 Enrollment ID: I20081211000713 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | William J L Newton |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1619907433 PECOS PAC ID: 9032281316 Enrollment ID: I20090519000499 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Paul M Haidak |
|---|---|
| Provider Type | Practitioner - Addiction Medicine |
| Provider Identifiers | NPI Number: 1871612515 PECOS PAC ID: 3971539446 Enrollment ID: I20090602000695 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Amanda D Bradley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851534606 PECOS PAC ID: 8022169580 Enrollment ID: I20090624000353 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | John Friedland |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1689654345 PECOS PAC ID: 2668474230 Enrollment ID: I20090806000817 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Isaac Joseph Mcfadden |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1316165079 PECOS PAC ID: 3870647506 Enrollment ID: I20090814000489 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Donald M Philpott |
|---|---|
| Provider Type | Practitioner - General Practice |
| Provider Identifiers | NPI Number: 1811941735 PECOS PAC ID: 3779612502 Enrollment ID: I20100603000493 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Oscar Hernandez-cano |
|---|---|
| Provider Type | Practitioner - Pulmonary Disease |
| Provider Identifiers | NPI Number: 1649266453 PECOS PAC ID: 7012986573 Enrollment ID: I20100831000359 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Richard A Bagby |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1164415543 PECOS PAC ID: 2567450695 Enrollment ID: I20100928001235 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Thomas Anderson Smith |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1023011764 PECOS PAC ID: 5799792032 Enrollment ID: I20101111000012 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Martin Jason Fiala |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1619961976 PECOS PAC ID: 8729152483 Enrollment ID: I20101117000490 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jennie Lynn Williams |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1841201472 PECOS PAC ID: 0042247934 Enrollment ID: I20110103000600 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Anisa Nayeem |
|---|---|
| Provider Type | Practitioner - Nephrology |
| Provider Identifiers | NPI Number: 1205922606 PECOS PAC ID: 6507866407 Enrollment ID: I20110729000123 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Sue A Richardson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376844357 PECOS PAC ID: 8729258850 Enrollment ID: I20110829000700 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | John Glen Carson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285943605 PECOS PAC ID: 3173795325 Enrollment ID: I20111011000692 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Deadra R Tucker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174828180 PECOS PAC ID: 5597930420 Enrollment ID: I20111205000696 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Karen R Maze |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518242650 PECOS PAC ID: 0042487266 Enrollment ID: I20120111000509 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Barry A Cortis |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1588825699 PECOS PAC ID: 8325206774 Enrollment ID: I20120215000282 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jamie N Hazard |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790052165 PECOS PAC ID: 4183884794 Enrollment ID: I20120319000622 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Ashley Michelle Dewitt |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1043476757 PECOS PAC ID: 2062662265 Enrollment ID: I20121024000729 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jennifer A Oneal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780948612 PECOS PAC ID: 3577708379 Enrollment ID: I20130327000384 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Katie L Goodman-hill |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831449990 PECOS PAC ID: 4587803549 Enrollment ID: I20130624000323 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Amanda Lynn Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1245457670 PECOS PAC ID: 6800035692 Enrollment ID: I20130627000469 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Frank Rao |
|---|---|
| Provider Type | Practitioner - Otolaryngology |
| Provider Identifiers | NPI Number: 1427030782 PECOS PAC ID: 4486657913 Enrollment ID: I20140207000534 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Holly Clem |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780008391 PECOS PAC ID: 4688806987 Enrollment ID: I20140421002040 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Roderick B Meese |
|---|---|
| Provider Type | Practitioner - Cardiovascular Disease (cardiology) |
| Provider Identifiers | NPI Number: 1336134642 PECOS PAC ID: 0547165565 Enrollment ID: I20150416002398 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Karen R Fox |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1306021712 PECOS PAC ID: 1355652835 Enrollment ID: I20150624003165 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Walter J Boyanton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1831135706 PECOS PAC ID: 3870500119 Enrollment ID: I20150729009219 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | John Michael Arnold |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1801093695 PECOS PAC ID: 8022266394 Enrollment ID: I20150817000262 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Anne Burnett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053780262 PECOS PAC ID: 4688983877 Enrollment ID: I20151029001766 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Fernando Dorrego |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1750771556 PECOS PAC ID: 6901107804 Enrollment ID: I20151218000715 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Robert W Gilbert |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1235346099 PECOS PAC ID: 5193861797 Enrollment ID: I20160226002064 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Misti Howell |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1649675281 PECOS PAC ID: 2769788256 Enrollment ID: I20160309001705 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Arthur W Davies |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1770821365 PECOS PAC ID: 6901081322 Enrollment ID: I20161018000746 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Sherrie L Smith |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1851740773 PECOS PAC ID: 8820376221 Enrollment ID: I20161104000837 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Ethan Kellum |
|---|---|
| Provider Type | Practitioner - Orthopedic Surgery |
| Provider Identifiers | NPI Number: 1396907705 PECOS PAC ID: 5092958199 Enrollment ID: I20161205000206 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Michelle S Val |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1699868943 PECOS PAC ID: 0648444984 Enrollment ID: I20161206001343 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Ronald Bonfiglio |
|---|---|
| Provider Type | Practitioner - Physical Medicine And Rehabilitation |
| Provider Identifiers | NPI Number: 1215944947 PECOS PAC ID: 4587552260 Enrollment ID: I20170307002357 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | James Cleveland Eldridge |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477951036 PECOS PAC ID: 0143507228 Enrollment ID: I20170426002620 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Melissa Smedley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1831638691 PECOS PAC ID: 5395018998 Enrollment ID: I20170901001555 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Adil H Khan |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1598044299 PECOS PAC ID: 8123394459 Enrollment ID: I20171031003382 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jolanta Szczarkowska |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1053363028 PECOS PAC ID: 6204194111 Enrollment ID: I20171226001712 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Monica Meeks |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144728031 PECOS PAC ID: 2264796184 Enrollment ID: I20180501001115 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mary Amanda Endsley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013410380 PECOS PAC ID: 1557616190 Enrollment ID: I20180621002207 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mary E Mcclain |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992244495 PECOS PAC ID: 6608152582 Enrollment ID: I20180709001956 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Clive Anderson Wasson |
|---|---|
| Provider Type | Practitioner - General Surgery |
| Provider Identifiers | NPI Number: 1215372768 PECOS PAC ID: 8729213442 Enrollment ID: I20180814002646 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jeremy Wayne Owens |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1639246739 PECOS PAC ID: 1557427929 Enrollment ID: I20180814003759 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Timothy A Crater |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1508845876 PECOS PAC ID: 0446285951 Enrollment ID: I20190114001111 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jason A. Martin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083173488 PECOS PAC ID: 2769724434 Enrollment ID: I20190429001818 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Christopher M Murray |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760833974 PECOS PAC ID: 1254624133 Enrollment ID: I20190828004106 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Melissa Ann Perry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023676335 PECOS PAC ID: 3173852597 Enrollment ID: I20190911000503 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Heather Ann Hyden |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1285292581 PECOS PAC ID: 1557690567 Enrollment ID: I20190916003470 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Courtney Jeannine Murray |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1164818365 PECOS PAC ID: 2365735792 Enrollment ID: I20191011001600 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Monica Gann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386290971 PECOS PAC ID: 7810323391 Enrollment ID: I20200130003348 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Karen Gayle Brazier |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568021483 PECOS PAC ID: 5496184509 Enrollment ID: I20200410000065 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Tara B Tye |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1093340630 PECOS PAC ID: 9638509524 Enrollment ID: I20200416001190 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Katelyn Denise Walker |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265068910 PECOS PAC ID: 7012348642 Enrollment ID: I20200514000354 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Brandi L. Thoma |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780204339 PECOS PAC ID: 6507287604 Enrollment ID: I20200527003139 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Erica Edwards |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1144851734 PECOS PAC ID: 4385065770 Enrollment ID: I20200611001520 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Sherry Barstad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1073952586 PECOS PAC ID: 5294153664 Enrollment ID: I20200916002587 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | David T Piskorowski |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1760802938 PECOS PAC ID: 4587958905 Enrollment ID: I20201016000732 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Amber N Sudberry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1710585914 PECOS PAC ID: 1052721115 Enrollment ID: I20201102001369 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Miranda Grider |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1053615013 PECOS PAC ID: 0042498875 Enrollment ID: I20201123003417 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Emma Shupp |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1225375538 PECOS PAC ID: 7012323777 Enrollment ID: I20210304002098 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Nevindra N Mangru |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1780636126 PECOS PAC ID: 8628484912 Enrollment ID: I20210311001050 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Michael Strickland |
|---|---|
| Provider Type | Practitioner - Urology |
| Provider Identifiers | NPI Number: 1528033537 PECOS PAC ID: 1355319609 Enrollment ID: I20210505000299 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Estefania Rivera Flores |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1891282620 PECOS PAC ID: 1254735962 Enrollment ID: I20210803001280 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mary Lisa Williams |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1356923189 PECOS PAC ID: 6204230147 Enrollment ID: I20210813002142 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Kaitlyn R Martin |
|---|---|
| Provider Type | Practitioner - Obstetrics/gynecology |
| Provider Identifiers | NPI Number: 1861920654 PECOS PAC ID: 5890064851 Enrollment ID: I20210909001573 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Julianna Michele Cook |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1992472815 PECOS PAC ID: 9032517545 Enrollment ID: I20211014001135 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Shannon Marie Foster |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1174849889 PECOS PAC ID: 9931432069 Enrollment ID: I20220603001318 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Amanda Stovall |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1457006249 PECOS PAC ID: 9830579853 Enrollment ID: I20220708001380 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | E'zoza Akhundjanova |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1366003683 PECOS PAC ID: 0648653956 Enrollment ID: I20220819000888 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jennifer Ward |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1114648490 PECOS PAC ID: 5890170542 Enrollment ID: I20220915001779 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Jacqueline R Smartt |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1285197426 PECOS PAC ID: 4486030285 Enrollment ID: I20221003000085 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mallory Reeves |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1912388687 PECOS PAC ID: 3274919865 Enrollment ID: I20221005001900 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Amy Hurst Evans |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1700897485 PECOS PAC ID: 1951338847 Enrollment ID: I20230310001201 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Mary Delphine Heath |
|---|---|
| Provider Type | Practitioner - Pediatric Medicine |
| Provider Identifiers | NPI Number: 1164518569 PECOS PAC ID: 7416321161 Enrollment ID: I20230320000794 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Kevin Thompson |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1649279274 PECOS PAC ID: 4789645243 Enrollment ID: I20230330003101 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Eric Bornemann |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972930733 PECOS PAC ID: 1456726611 Enrollment ID: I20230331002258 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Kay Fearing |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124801493 PECOS PAC ID: 3375998529 Enrollment ID: I20231009002496 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
| Provider Name | Hailey Puckett |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1164295408 PECOS PAC ID: 8820447477 Enrollment ID: I20231208000682 |
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
News Archive
The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.
Labopharm Inc. today announced that it has priced an underwritten public offering of 11,764,706 newly issued units at a public offering price of US$1.70 per unit. Each unit is comprised of one of the Company's common shares and a warrant to purchase 0.5 of a common share. Each whole warrant entitles the holder to acquire one common share of the Company upon payment of US$2.30 per share, exercisable at any time during the period beginning six months after the date of issuance and ending three years following the date of issuance.
Three major Ohio universities and four hospitals have joined with the March of Dimes Foundation to establish a new collaborative research program aimed exclusively at finding the unknown causes of premature birth.
The Supreme Court justice's ruling affects a number of faith-based groups. She asked for an administration response by tomorrow.
Reducing the amount of time spent sitting down should be part of public health policy following COVID-19, says a new report from a study by the University of Huddersfield.
› Verified 8 days ago
Southern Tennessee Primary Care - Walker Family Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 183 Hospital Rd, Suite D, Winchester, TN 37398 Phone: 931-967-8222 Fax: 931-967-8226 | |
Amg-southern Tennessee Llc Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 2118 Cowan Hwy, Winchester, TN 37398 Phone: 931-962-4040 Fax: 931-962-2277 | |
Stephen Scott Sommerschield Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2230 Cowan Hwy Ste B, Winchester, TN 37398 Phone: 931-962-1345 Fax: 931-967-6439 | |
Center For Internal Medicine Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 161 Shirley Dr, Winchester, TN 37398 Phone: 931-967-0872 | |
Donald M. Philpott, Md Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 155 Hospital Rd, Suite B, Winchester, TN 37398 Phone: 931-962-4040 Fax: 931-962-2277 | |
Hello Healthy Pllc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 1830 Sharp Springs Rd, Winchester, TN 37398 Phone: 931-444-7639 Fax: 308-888-6702 |